Introduction: The treatment of advanced gastric cancer is rapidly evolving from conventional chemotherapy to biomarker-driven precision medicine. Claudin 18.
Introduction:
The treatment of advanced gastric cancer is rapidly evolving from conventional chemotherapy to biomarker-driven precision medicine. Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed in gastric epithelial cells and many gastric cancers, has emerged as one of the most promising therapeutic targets.
Why was this review needed?
Following the approval of zolbetuximab for HER2-negative, CLDN18.2-positive advanced gastric cancer, numerous CLDN18.2-targeted therapies are under development. This review summarizes the current evidence and future directions of this rapidly expanding therapeutic field.
What did the review show?
Clinical Impact:
Routine assessment of CLDN18.2 expression is becoming increasingly important in advanced gastric cancer. Expanding CLDN18.2-directed therapies are expected to broaden personalized treatment options and improve outcomes for appropriately selected patients.
Take-Home Message:
CLDN18.2 has emerged as a major therapeutic target in gastric cancer, marking a shift toward biomarker-guided treatment. As monoclonal antibodies, ADCs, bispecific antibodies, and CAR-T therapies continue to evolve, precision targeting of CLDN18.2 is poised to become a cornerstone of future gastric cancer management.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.